Partial Amelioration of Synaptic and Cognitive Deficits by Inhibiting Cofilin Dephosphorylation in an Animal Model of Alzheimer’s Disease

Animals

All experiments were performed with the approval of State University of New York at Buffalo Animal Care Committee. The transgenic mice carrying 5 familial AD mutations on human amyloid precursor protein (APP, K670N/M671L + I716V + V717I) and human presenilin 1 (PS1, M146L+ L286V), 5×FAD, were a generous gift from Dr. William E. Van Nostrand (Stony Brook University). Genotyping were performed by PCR according to the manufacturer’s protocol [19, 20].

Primary neuronal culture

Rat cortical cultures were prepared as we previously described [21]. Briefly, frontal cortex was dissected from Sprague-Dawley rat embryos (E18), and cells were dissociated using trypsin and titurated through a Pasteur pipette. The neurons were plated on coverslips coated with poly-L-lysine in DMEM with 10% fetal calf serum at a density of 5 × 10⁴ cells/cm² or 1 × 10⁶ cells/cm². Low density neuronal cultures were used for immunostaining, while high density neurons were used for biochemical experiments. When neurons attached to the coverslip within 24 hours, the medium was changed to neurobasal media (Invitrogen) with B27 supplement. Cytosine arabinoside (Arac, 5 μM) was added at DIV3 to stop glial proliferation. Neurons were maintained for 2-3 weeks before being used.

Reagents

The procedure of Aβ oligomer preparation was similar to what was described before [22–24]. In brief, the Aβ_1–42 peptide (Tocris) was dissolved in hexafluoroisopropanol to 1 mM. Hexafluoroisopropanol was then removed under vacuum. The remaining peptide was then resuspended in DMSO to 5 mM and diluted in H₂O to 0.1 mM. The oligomeric Aβ was formed by incubating at 4°C for 24 h. The TAT-conjugated, phosphorylated cofilin peptide derived from 1–16 residues of cofilin with Ser3 phosphorylation (MAS^PGVAVSDGVIKVFN) was designed to act as a cell-permeable inhibitor of endogenous cofilin dephosphorylation (competes for binding to phosphatases) [25–28]. The scrambled TAT peptide or non-phosphorylated cofilin peptide served as negative controls.

Electrophysiological recordings in slices

Standard whole-cell voltage-clamp recordings were used to measure synaptic currents in layer V medial PFC pyramidal neurons as we described previously [27, 29]. Mice were sacrificed after inhaling Halothane (Sigma, St Louis, MO, USA). Brains were immediately removed, iced and cut into 300 μm slices by a Vibratome (Leica VP1000S, Leica Microsystems Inc., Buffalo Grove, IL, USA). Slices were then incubated in artificial cerebrospinal fluid (ACSF, in mM: 130 NaCl, 26 NaHCO₃, 3 KCl, 5 MgCl₂, 1.25 NaH₂PO₄, 1 CaCl₂, 10 glucose, pH 7.4, 300 mOsm) for 1–6 h at room temperature (20-21°C) bubbling with 95% O₂, 5% CO₂. Prefrontal cortex-containing slices were positioned in a perfusion chamber attached to the fixed stage of an upright microscope (Olympus, Center Valley, PA, USA) and submerged in continuously flowing oxygenated ACSF. Bicuculline (10 μM) and CNQX (25 μM) were added in NMDAR-EPSC recordings. Bicuculline and D-APV (25 μM) were added in AMPAR-EPSC recordings.

Patch electrodes contained internal solution (in mM): 130 Cs-methanesulfonate, 10 CsCl, 4 NaCl, 10 HEPES (N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid), 1 MgCl₂, 5 ethylene glycol tetraacetic acid, 2.2 QX-314, 12 phosphocreatine, 5 MgATP, 0.2 Na₂GTP, 0.1 leupeptin, pH 7.2–7.3 and 265–270 mOsm. Cells were visualized with a 40x water-immersion lens and illuminated with near infrared light and the image was detected with an infrared-sensitive CCD camera. A Multiclamp 700 A amplifier was used for these recordings. Tight seals (2–10 GΩ) from visualized neurons were obtained by applying negative pressure. With additional suction, the membrane was disrupted into the whole-cell configuration. Evoked EPSC were generated with a pulse from a stimulation isolation unit controlled by a S48 pulse generator (Astro Med, West Warwick, RI, USA). A bipolar stimulating electrode (FHC, Bowdoinham, ME, USA) was placed ∼100 μm from the neuron under recording. Membrane potential was maintained at –70 mV for AMPAR-EPSC recordings. For NMDAR-EPSC, the cell (clamped at –70 mV) was depolarized to +60 mV for 3 s before stimulation to fully relieve the voltage-dependent Mg^2 + block. To obtain the input-output responses, EPSC was elicited by a series of stimulation intensities with the same duration of pulses.

Western blotting

After treatment, slices or cultures were homogenized in boiling 1% SDS. After centrifugation (13,000 × g, 20 min), the supernatant fractions were subjected to 7.5% or 10% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. The blots were blocked with 5% nonfat dry milk for 1 h at room temperature, followed by incubation with various primary antibodies including anti-cofilin (1:250; Cell Signaling Technology, 2601, or 1:2000; Cell Signaling Technology, 5175), anti-^ser3p-cofilin (1:500; Cell Signaling Technology, 3310), anti-LIMK1 (1:500; BD Transduction Laboratories, 611748), anti-p-^T508LIMK1/ ^T505LIMK2 (1:500, Abcam, ab131341), anti-PSD-95 (1:1000; Neuromab, 75-028), anti-tubulin (1:10000; Sigma, T9026), anti-Slingshot (SSH) (1:500; Ecm Bioscience, SP1711) and anti-synaptophysin (1:500; Chemicon, MAB332). The blots were exposed to the enhanced chemiluminescence substrate (Amersham Biosciences). Quantitation was obtained from densitometric measurements of immunoreactive bands on films.

Biochemical measurement of surface-expressed receptors

The surface NMDA and AMPA receptors were detected as described previously [29, 30]. In brief, after treatment, cortical slices were incubated with ACSF containing 1 mg/ml sulfo-N-hydroxysuccinimide- LC-Biotin (Pierce Chemical Co., Rockford, IL) for 20 min on ice. The slices were then rinsed three times in Tris-buffered saline to quench the biotin reaction, followed by homogenization in 300 μl of modified radioimmunoprecipitation assay buffer (1% Triton X-100, 0.1% SDS, 0.5% deoxycholic acid, 50 mM NaPO₄, 150 mM NaCl, 2 mM EDTA, 50 mM NaF, 10 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, and 1 mg/ml leupeptin). The homogenates were centrifuged at 14,000 × g for 15 min at 4°C. Protein (15 μg) was removed to measure total NR1. For surface protein, 150 μg of protein was incubated with 100 μl of 50% Neutravidin Agarose (Pierce Chemical Co.) for 2 h at 4°C, and bound proteins were resuspended in 25 μl of SDS sample buffer and boiled. Quantitative western blots were performed on both total and biotinylated (surface) proteins using anti-NR1 (1:500; Cell signaling, 5704, or 1:500; Neuromab, 75-272), anti-NR2A (1:500; Millipore, 07-632), anti-NR2B (1:500; Millpore, 06600), anti-GluR1 (1:500; Millipore, AB1504), anti-GluR2 (1:500; Neuromab, 75-002), and anti-GABA_AR β3 (1:500; NeuroMab, 75-149).

Synpatosomal fraction and measurement of synaptic proteins

Subcellular fractions were prepared as we described previously [23, 27]. In brief, blocks of frontal cortex were homogenized in ice-cold lysis buffer. 50 μl of homogenates were saved as the total protein, and the remaining homogenates were subjected to several steps of centrifugation. After centrifugation at 800 × g for 5 min to remove nuclei and large debris, the remaining supernatant was subjected to 10,000 × g centrifugation for 10 min. The crude synaptosome fraction (pellet) was suspended in lysis buffer containing 1% Triton X-100 and 300 mM NaCl, homogenized again, and centrifuged at 16,000 × g for 30 min to obtain Triton soluble fraction (P1) and Triton insoluble fraction (P2). Triton insoluble fraction which mainly includes membrane-associated proteins from synpatosomes was dissolved in 1% SDS. Samples were boiled in 2 × SDS loading buffer for 5 min, and separated on 7.5% SDS-PAGE. Western blots were performed using antibodies against actin (1:1000; Santa Cruz, sc-1616) and PSD-95 (1:1000; Neuromab, 75-028).

Immunocytochemistry

After Aβ treatment, neurons cultured on coverslips (DIV 14) were fixed in 4% paraformaldehyde in PBS for 20 min at room temperature and washed 3 times with PBS. After permeabilization with 0.1% Triton X-100 in PBS for 20 min, neurons were incubated with 5% bovine serum albumin for 1 h to block nonspecific staining. Next, neurons were incubated with primary antibodies at 4°C overnight, including anti-NeuN (1:1000; Millipore, MAB377) and anti-MAP2 (1:500; Santa Cruz, sc-20172). After washing, neurons were incubated with Alexa Fluor 594-conjugated secondary antibody (1:250, Invitrogen) and Alexa Fluor 488-conjugated secondary antibody (1:250, Invitrogen) for 2 h at room temperature. After washing in PBS for three times, the coverslips were mounted on slides with VECTASHIELD mounting media (Vector Laboratories, Burlingame, CA). Fluorescence images were obtained using a 20 × lens and were captured digitally using SPOT basic image capture software. All specimens were imaged under identical conditions and analyzed using identical parameters.

Behavioral tests

Behavioral experimenters were blind to the treatments that animals received. To test working memory, the T-maze delayed alternation task was used as we previously described [31, 32]. Mice (2.5–4 months) were subjected to restricted diet and maintained at approximately 85% of their original weight for 1–2 week. They were habituated to a T-maze until they voluntarily ate a sucrose pellet placed at the end of each arm. T-maze training began only after habituation had finished and when mice showed no visual signs of distress of being in the maze. On the first trial, animals were rewarded for entering either arm. Thereafter, for a total of 11 trials per session, animals were rewarded only if they entered the arm opposite to the one that was previously chosen. Between trials the choice point was wiped with alcohol to remove olfactory cues. In the initial 1-2 training sessions, the delay between trials started at 5 s, and was subsequently raised in 5-s intervals. In the later training sessions, the delay was fixed at 30 s, and animals were examined daily until establishing baseline performance of 60–70% correct for two consecutive days. The first trial was never included in assessingperformance.

Novel object recognition (NOR) task was conducted with minor modifications [33]. The first day of each experiment consisted of 2-3 habituation trials (3 min each, 5 min apart), during which mice explored the arena (44.5 cm in diameter) alone (no objects) in the training room. Twenty-four hours later, the experimental trials began, which consisted of a familiarization phase (phase 1) and a test phase separated by a delay period. During the familiarization phase, mice were placed in the arena containing two copies of an object (A) and allowed to freely explore (3 min per trial). After a short (5 min) delay period, a test trial (3 min) was conducted. Mice were returned to the arena containing one of the original objects (“familiar-A”) and a new, different object (“novel-B”). All objects were made of plastic toys (height: about 5 cm) with similar textures, colors, and sizes, but distinctive shapes. The objects were positioned in two adjacent corners, 10 cm from the walls. The arena and objects were cleaned between each trial with 70% alcohol to mask any olfactory cues. The room was illuminated by indirect white light. Exploration was defined by sniffing or touching the object with the nose. Sitting on the object was not considered exploration. Total exploration time(s) of the familiar and novel objects was recorded and used to calculate a discrimination index (time spent with novel object (B) - time spent with familiar object (A))/ (total time exploring both objects (B+A)) for training and test sessions. This index was used to measure recognition memory.

Data analysis

Data analyses were performed with Clampfit (Molecular Devices), Kaleidagraph (Abelbeck/Synergy Software, Reading, PA), Mini Analysis Program (Synaptosoft, Leonia, NJ, USA), and ImageJ software (National Institutes of Health). Experiments with two groups were analyzed statistically using unpaired Student’s t-tests. Experiments with more than two groups were subjected to one-way ANOVA, followed by post hoc Tukey tests.

FAD transgenic mice exhibit the impaired NMDAR and AMPAR surface expression and synaptic currents

To test the potential impairment of excitatory transmission in AD, we examined the expression of NMDAR and AMPAR subunits in FAD mice (2.5-month-old). The prefrontal cortex (PFC), a brain region controlling high-level cognitive processes and exhibiting structural and functional abnormalities at the early stage of AD [34], was mainly used in our studies. We found that the level of surface NMDAR and AMPAR subunits was significantly lower in PFC slices from FAD mice, compared to age-matched wild-type (WT) mice (Fig. 1A, B, NR1: 53.3 ± 6.3% of WT; NR2A: 53.5 ± 8.2% of WT; NR2B: 58.8 ± 8.3% of WT; GluR1: 61.5 ± 6.1% of WT; GluR2: 56 ± 6.6% of WT, n = 9, p < 0.001,t-test). In contrast, the level of surface GABA_AR, the major inhibitory receptor in the central nervous system, was not significantly changed (Fig. 1A, B, n = 3). The level of total NMDAR and AMPAR subunits was not significantly altered in 2.5-month-old FAD mice (Fig. 1A, B, n = 9). It suggests that FAD mice have the diminished number of glutamate receptors at the plasma membrane.

Next, we compared the NMDAR- and AMPAR-mediated synaptic currents in PFC slices from WT and FAD mice (2.5 months old). As shown in Fig. 2A and B, AMPAR-EPSC and NMDA-EPSC induced by a series of stimulus intensities were markedly reduced in PFC pyramidal neurons from FAD mice, compared to those from WT mice (NMDA: 45% –69% decrease, n = 13 per group; AMPA: 56% –64% decrease, n = 16–21 per group, p < 0.001, ANOVA). The loss of cortical NMDAR and AMPAR function in FAD mice may be attributed to the reduced glutamate receptor delivery to the synaptic membrane.

Cofilin phosphorylation and synaptic F-actin are altered in AD conditions

Since the dynamics of actin cytoskeleton plays a key role in regulating NMDAR and AMPAR membrane trafficking [12, 35–37], we examined whether actin regulators were altered in FAD mice. We found that the amount of phosphorylated cofilin was significantly decreased in PFC slices from FAD mice (Fig. 3A, B, 54.2 ± 6.5% of WT, n = 8, p < 0.01, t-test), while the total cofilin was unchanged, suggesting that non-phosphorylated cofilin is increased in FAD mice, consistent with the previously reported cofilin hyperactivation in AD patients [7, 8]. The protein level of Slingshot, the phosphatase dephosphorylating and activating cofilin, was not altered in FAD mice (Fig. 3A, B, n = 8, p > 0.05, t-test). LIMK1, the kinase phosphorylating and inactivating cofilin, as well as the phosphorylated and active form of LIMK, p-^T508LIMK1/ ^T505LIMK2, had similar expression in WT and FAD mice (Fig. 3A, B, n = 8, p > 0.05, t-test). No significant changes were observed with the scaffolding protein PSD-95, a postsynaptic marker (Fig. 3A, B, n = 8, p > 0.05,t-test).

Nest, we tested the direct effect of Aβ_1–42 treatment (1 μM, 7-day) on cofilin and synaptic proteins in cortical cultures. As shown in Fig. 3C and D, phospho-cofilin level was significantly decreased in Aβ-treated cultures (75.3 ± 5.2% of control, n = 7, p < 0.01, t-test), consistent with what we detected in FAD mice, while the protein level of total cofilin was unchanged. No significant change was found on the expression of synaptophysin (a presynaptic marker) and PSD-95 (a postsynaptic marker) with Aβ treatment (Fig. 3C, D), suggesting that synapses have been maintained. Taken together, these results suggest that cofilin is activated by Aβ before synapse lossoccurs.

To measure cell viability after Aβ treatment, we performed MAP2 (a dendritic marker) and NeuN (a neuronal nuclear marker) co-staining experiments. Neurons were measured by counting MAP2+/NeuN+ neurons in cortical cultures. As shown in Fig. 3E and F, Aβ treatment did not significantly alter cell viability, as demonstrated by the normal neuronal density (p > 0.05, t-test).

To find out whether the reduced phospho-cofilin in FAD mice may lead to the alteration of actin filaments, we compared the G-actin (Triton-soluble monomeric actin) and F-actin (Triton-insoluble filamentous actin) in the synaptic fraction of frontal cortex from WT versus FAD mice, using the approach similar to what was previously described [27, 38]. We found that the level of total actin or G-actin at the synaptic cytosol (soluble) was largely unchanged, but the level of synaptic F-actin (insoluble) was significantly higher in FAD mice, compared to WT mice (Fig. 3G, H, 80.4% ± 19.4% increase, n = 5 pairs, p < 0.05, t-test). The F/G actin ratio was alsoelevated in FAD mice (Fig. 3G, H, 93.2% ± 23.7% increase, n = 5 pairs, p < 0.05, t-test), consistent with the Aβ-induced enhancement of actin polymerization in cultured hippocampal neurons and PC12 cells [39, 40]. In contrast, PSD-95 did not show significant changes in synaptic fractions. These data suggest that the dynamics of actin filaments is altered in AD.

Inhibiting cofilin dephosphorylation partially rescues synaptic deficits in FAD mice

Given the decreased phospho-cofilin in FAD mice, we tested whether inhibiting cofilin dephosphorylation could rescue the synaptic deficits in FAD mice. A peptide consisting of 1–16 residues of Ser3-phosphorylated cofilin was used as an inhibitor of endogenous cofilin dephosphorylation [27, 42]. The p-cofilin peptide is presumed to bind to endogenous cofilin phosphatases, therefore preventing the dephosphorylation of endogenous cofilin. To render the p-cofilin peptide cell permeable, it was coupled to the protein transduction domain of the human immunodeficiency virus (HIV) TAT protein. Previous studies have demonstrated that systemic injections can reliably deliver TAT peptides into CNS neurons [27, 44]. Thus, we gave i.v. injections of TAT-p-cofilin peptide (10 pmol/g, once daily for 7 days) to animals. As shown in Fig. 4A and B, the systemic administration of TAT-p-cofilin peptide led to a significant increase of endogenous p-cofilin, but not total cofilin, in cortical slices of FAD mice. It suggests that the TAT-p-cofilin peptide indeed inhibits the dephosphorylation of endogenous cofilin in the brain.

Next, we examined NMDAR and AMPAR surface expression after i.v. injections of TAT-p-cofilin peptide (10 pmol/g, 7 days) in FAD mice. As shown in Fig. 4C and D, compared to wild-type mice, the levels of surface NMDAR and AMPAR subunits were significantly diminished in FAD mice injected with TAT control peptide (NR1, 47.8 ± 1.4% of WT, NR2A: 47.2 ± 4.6% of WT, NR2B, 51.1 ± 3.7% of WT, GluR1, 50.1 ± 6.5% of WT, GluR2, 55 ± 8.3% of WT, n = 7), but these surface receptors were partially recovered in FAD mice injected with TAT-p-cofilin peptide (NR1, 67.6 ± 8.2% of WT; NR2A, 79.1 ± 5.9% of WT; NR2B, 76.3 ± 3.8% of WT, GluR1, 83.8 ± 8.7% of WT; GluR2, 87.9 ± 4.1% of WT, n = 7, p < 0.05, ANOVA, compared to FAD+control peptide). These data suggest that inhibition of cofilin dephosphorylation can result in the partial restoration of glutamate receptor membrane delivery in FAD mice.

We further examined whether AMPAR- and NMDAR-mediated synaptic transmission could be restored in FAD mice after i.v. injections of TAT-p-cofilin peptide (10 pmol/g, 7 days). As shown in Fig. 5A and B, the input/output curves of AMPAR-EPSC and NMDAR-EPSC in PFC pyramidal neurons had partial recovery in FAD mice injected with TAT-p-cofilin peptide (AMPA: 40–80% increase, compared to TAT-injected FAD mice, n = 5–10 per group, n = NMDA: 35–50% increase, compared to TAT-injected FAD mice, n = 8–14 per group, p < 0.05, ANOVA, FAD+p-cofilin pep. versus FAD+TAT pep.). Neither the AMPAR- nor the NMDAR-mediated synaptic response has completely returned to the level of wild-type animals. Thus, cofilin inhibition can result in the partial recovery of glutamatergic transmission in FAD mice.

Inhibiting cofilin dephosphorylation partially ameliorates cognitive impairment in FAD mice

To determine the functional consequences of inhibiting cofilin dephosphorylation in FAD mice, we examined working memory (WM), a key cognitive process relying on PFC glutamatergic transmission [29, 46], and novel object recognition (NOR) memory, another cognitive process involving PFC [47].

WM was assessed using the T-maze alternation task [31, 32]. A significant reduction of the percentage correctness of choices in the T-maze testing was observed in FAD mice (4-month-old), compared to age-matched WT mice (Fig. 6A, WT: 72 ± 2%, n = 10; FAD: 48 ± 2.6%, n = 9, p < 0.01, ANOVA). Injections with the TAT-p-cofilin peptide partially alleviated the WM deficit in FAD mice, while TAT control peptide or non-phosphorylated cofilin peptide, TAT-cofilin peptide, was ineffective (Fig. 6A, TAT: 50 ± 2.6%, n = 8; TAT-p-cofilin: 60 ± 2.3%, n = 9, TAT-cofilin: 47.5 ± 6.3%, n = 4, F_4,39 = 23.2, p < 0.05, ANOVA).

To determine the influence of cofilin dephosphorylation inhibition in individual FAD mice, we performed T-maze tests on the same mice before and after peptide injections. As shown in Fig. 6B, most of the FAD mice (5/6) had improved WM performance after 7-day TAT-p-cofilin peptide injections, while no improvement was found in FAD mice injected with TAT control peptide (n = 4).

To further confirm the impact of cofilin inhibition on cognitive functions in FAD mice, we measured the Novel Object Recognition (NOR) task, a fundamental explicit memory process requiring judgments of the prior occurrence of stimuli based on the relative familiarity of individual objects [48, 49]. As shown in Fig. 7A, WT mice (4-month-old) spent much more time exploring the novel object in the test phase (familiar object: 15.9 ± 3.7 s, novel object: 36.7 ± 6.2 s, n = 9, p < 0.01, t-test), whereas FAD mice (4-month-old) lost the preference to the novel object (familiar object: 13.4 ± 4.3 s; novel object: 9 ± 2.7 s, n = 7, p > 0.05, t-test). After TAT-p-cofilin peptide injections for 7 days, FAD mice showed an increased trend in exploring the novel object (familiar object: 18.3 ± 4.7 s, novel object: 25.5 ± 6.0 s, n = 7), while injections with control peptides (TAT-peptide or TAT-cofilin peptide) were ineffective (TAT, familiar object: 21.5 ± 4.3 s, novel object: 19.5 ± 3.7 s, n = 7; TAT-cofilin, familiar object: 17.6 ± 1.3 s, novel object: 11.2 ± 1.3 s, n = 4). The discrimination index (DI) of NOR task, which indicates the differential time in exploring the novel versus familiar object, was significantly impaired in FAD mice (Fig. 7B, WT: 0.44 ± 0.08, n = 9, FAD: –0.18 ± 0.02, n = 7; p < 0.001, ANOVA). Injecting TAT-p-cofilin peptide to FAD mice led to the partial recovery of NOR recognition memory (Fig. 7B, TAT-p-cofilin: 0.14 ± 0.06, n = 7, TAT: –0.11 ± 0.09, n = 7; TAT-cofilin: –0.23 ± 0.03, n = 4, p < 0.05, ANOVA). These data suggest that inhibition of cofilin dephosphorylation can result in the partial recovery of cognitive functions in FAD mice.